Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances

Core Insights - Recursion Pharmaceuticals, Inc. is leveraging artificial intelligence and machine learning to enhance drug discovery, particularly in rare diseases and oncology [1] - The company achieved a significant milestone with a $12.5 million payment from Rallybio for the advancement of its investigational drug REV102 [2] - Recent technological advancements include the launch of Boltz-2, developed in collaboration with MIT, to improve predictions for small molecule–protein interactions [3] Company Developments - Recursion's pipeline includes six lead candidates, with four focused on oncology and two on rare diseases, with key assets like REC-aK7 and REC-4881 progressing in clinical trials [4] - The company has made strides in regulatory progress for rare disease assets and has expanded collaborations with institutions such as MIT, Tempus, and HealthVerity [5] - Investor engagement is increasing, highlighted by presentations at events like Needham's healthcare session in New York [5]